Page 6 - அகஸ்டா பல்கலைக்கழகம் மருத்துவ கல்லூரி ஆஃப் ஜார்ஜியா News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Sickle cell scientist fights for a cure | NewsChannel 3-12
keyt.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from keyt.com Daily Mail and Mail on Sunday newspapers.
Sickle cell scientist fights for a cure
kesq.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kesq.com Daily Mail and Mail on Sunday newspapers.
Scientist with sickle cell fights for a cure
localnews8.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from localnews8.com Daily Mail and Mail on Sunday newspapers.
A new study from Augusta University’s Medical College of Georgia has linked high-dose CBD to multiple benefits associated with early-onset familial Alzheimer’s disease, including improved cognition and restored function in proteins responsible for clearing plaque from the brain. In addition, the CBD was found to reduce levels of a protein linked with the excessive inflammation found in Alzheimer’s patients.
Alzheimer’s disease is a growing public health issue that is expected to become a major problem as the world’s populations live to older ages. The disease is linked to a build-up of beta-amyloid plaques and other ‘debris’ in patients’ brains, the reasons for which may be due to a variety of genetics, lifestyle factors, and more.
SHARE
ASCO GU 2021: TIVO-3: Tivozanib in Patients with Advanced Renal Cell Carcinoma Who Have Progressed After Treatment with Axitinib
Published 14 February 2021
(UroToday.com) Tivozanib is a potent and highly selective VEGF receptor tyrosine kinase inhibitor in clinical development for renal cell carcinoma (RCC). Axitinib is also a potent and selective VEGF-receptor inhibitor now commonly part of front-line advanced RCC treatment. In the TIVO-3 trial, tivozanib demonstrated significantly greater progression-free survival (PFS) (hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.56-0.94) and objective response rate (ORR) (15.2% versus 7.5%, p=0.003) versus sorafenib in the intention to treat population, in the subset of patients treated with two prior VEGFR-tyrosine kinase inhibitors (TKI), and in patients treated with a prior VEGFR-TKI and an anti-PD-1 antibody.